Format

Send to

Choose Destination
Breast. 2015 Nov;24 Suppl 2:S56-9. doi: 10.1016/j.breast.2015.07.014. Epub 2015 Aug 15.

Obesity, insulin resistance and breast cancer outcomes.

Author information

1
Department of Medicine, Division of Medical Oncology and Hematology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada; Division of Clinical Epidemiology, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada. Electronic address: pgoodwin@mtsinai.on.ca.

Abstract

There is growing evidence that obesity is associated with poor outcomes in early stage breast cancer. This paper addresses four current areas of focus: 1. Is obesity associated with poor outcomes in all biologic subtypes of breast cancer? 2. Does obesity effect AI efficacy or estrogen suppression in the adjuvant setting? 3. What are the potential biologic underpinnings of the obesity-breast cancer association? 4. Are intervention studies warranted? If so, which interventions in which populations? Research is needed to resolve these questions; intervention trials involving lifestyle interventions or targeting the biology postulated to link obesity and cancer are recommended.

KEYWORDS:

Adjuvant; Aromatase inhibitors; Biology; Breast cancer; Intervention; Obesity

PMID:
26283600
DOI:
10.1016/j.breast.2015.07.014
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center